Sun Pharmaceutical Industries is aiming to gain market share in all the verticals it is present in amid challenges posed by the coronavirus pandemic. The drug major, which has presence in around 150 countries, caters to various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others.
The company is also looking at supply chain protection, ensuring optimum utilisation of its factories and working closely with vendors to ensure continuity of supply while at the same time continuing focus on improving productivity throughout. In times of COVID-19, the company also looks to focus on cash preservation and finding a way to reduce the overall debt for the company.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1870.45 |
| Dr. Reddys Labs. | 1345.95 |
| Cipla | 1455.60 |
| Zydus Lifesciences | 1100.20 |
| Lupin | 2399.60 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: